Literature DB >> 8551275

Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients.

A Sarasini1, F Baldanti, M Furione, E Percivalle, R Brerra, M Barbi, G Gerna.   

Abstract

Four human cytomegalovirus (HCMV) isolates from four different AIDS patients treated with both ganciclovir and foscarnet and not responding clinically to antiviral treatment, were studied in order to verify the occurrence of double resistance to both drugs, and to define whether single or multiple HCMV strains could be responsible for the double resistance. Peripheral blood leukocytes (PBL), the relevant conventional viral isolates, and plaque-purified strains from all four patients were examined by antiviral drug susceptibility testing by an immediate-early antigen plaque reduction assay and by restriction fragment length polymorphism (RFLP) analysis using polymerase chain reaction (PCR)-amplified multiple genome regions and endonucleases. All four HCMV strains had a high level of resistance to both ganciclovir and foscarnet. A single HCMV strain was shown to be responsible for the dual resistance in each patient. HCMV strain identity and uniqueness were shown for each of the four patients in blood samples, viral isolates, and plaque-purified strains. In addition, in two patients the same single HCMV strain shifted progressively from drug sensitivity to ganciclovir and then to ganciclovir-foscarnet resistance. These findings document that resistance to both ganciclovir and foscarnet of HCMV strains recovered from blood of AIDS patients represents an emerging problem. Although it is known that multiple HCMV strains may cocirculate in the blood of AIDS patients, single strains appear to be responsible for the dual resistance. Molecular mechanisms responsible for the double resistance of the four reported strains are under study.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8551275     DOI: 10.1002/jmv.1890470309

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS.

Authors:  F Baldanti; M R Underwood; S C Stanat; K K Biron; S Chou; A Sarasini; E Silini; G Gerna
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

2.  Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection.

Authors:  G Gerna; M Zavattoni; E Percivalle; P Grossi; M Torsellini; M G Revello
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

3.  Antiviral properties of a series of 1,6-naphthyridine and 7, 8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus.

Authors:  J Bedard; S May; L L'Heureux; T Stamminger; A Copsey; J Drach; J Huffman; L Chan; H Jin; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

4.  How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.

Authors:  Kathryn L Springer; Sunwen Chou; Shaobing Li; Roger H Giller; Ralph Quinones; James E Shira; Adriana Weinberg
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.

Authors:  I Buerger; J Reefschlaeger; W Bender; P Eckenberg; A Popp; O Weber; S Graeper; H D Klenk; H Ruebsamen-Waigmann; S Hallenberger
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir.

Authors:  J Bedard; S May; M Lis; L Tryphonas; J Drach; J Huffman; R Sidwell; L Chan; T Bowlin; R Rando
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

7.  Inactivation of enveloped virus by laser-driven protein aggregation.

Authors:  Shaw-Wei D Tsen; Travis Chapa; Wandy Beatty; Kong-Thon Tsen; Dong Yu; Samuel Achilefu
Journal:  J Biomed Opt       Date:  2012-12       Impact factor: 3.170

8.  Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.

Authors:  T Cihlar; M D Fuller; J M Cherrington
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Authors:  Annalisa Macagno; Nadia L Bernasconi; Fabrizia Vanzetta; Erica Dander; Antonella Sarasini; Maria Grazia Revello; Giuseppe Gerna; Federica Sallusto; Antonio Lanzavecchia
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

10.  Rhesus cytomegalovirus is similar to human cytomegalovirus in susceptibility to benzimidazole nucleosides.

Authors:  Thomas W North; Getachew Sequar; Leroy B Townsend; John C Drach; Peter A Barry
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.